← Eichor
Condition: Diffuse Sclerosis Systemic Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Diffuse Sclerosis Systemic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Periodontal Microbiota in Systemic Sclerosis
NA · 1 location(s) · University Hospital, Strasbourg, France · NCT06182293US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
NA · 5 location(s) · Primus Pharmaceuticals · NCT06256575A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT05251415Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2 · 92 location(s) · Novartis Pharmaceuticals · NCT06655896Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Phase N/A · 1 location(s) · Hacettepe University · NCT07183072Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Phase N/A · 1 location(s) · Université Catholique de Louvain · NCT07000916Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
Phase 2 · 9 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06375005A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
Phase N/A · 1 location(s) · Hacettepe University · NCT07182981Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Phase 2 · 2 location(s) · Johns Hopkins University · NCT04797286A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Phase N/A · 1 location(s) · Duke University · NCT03276923Scleroderma Registry & Repository at the Hospital for Special Surgery
Phase N/A · 1 location(s) · Hospital for Special Surgery, New York · NCT01656447Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Phase 2 · 1 location(s) · Hospital for Special Surgery, New York · NCT03844061Rheumatology Patient Registry and Biorepository
Phase N/A · 1 location(s) · Yale University · NCT04402086Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi
NA · 1 location(s) · Hacettepe University · NCT07292961TENS in Scleroderma
Phase 1 · 1 location(s) · University of Michigan · NCT06646913Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies
NA · 1 location(s) · University Hospital, Strasbourg, France · NCT04917705Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
Phase 1 · 1 location(s) · Shenzhen MagicRNA Biotechnology Co., Ltd · NCT06801119A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Ass
Phase 3 · 10 location(s) · GlaxoSmithKline · NCT06716606Rheumatology Diet Study
Phase N/A · 1 location(s) · University of Central Florida · NCT06339957Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
Phase N/A · 9 location(s) · Peking Union Medical College Hospital · NCT06417502A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Phase 1 · 1 location(s) · Xencor, Inc. · NCT07284797AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Stud
Phase 2 · 52 location(s) · Artiva Biotherapeutics, Inc. · NCT06991114Platform Clinical Study for Conquering Scleroderma
Phase 2 · 34 location(s) · Scleroderma Research Foundation, Inc. · NCT06195072Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis
Phase 1/Phase 2 · 1 location(s) · UMC Utrecht · NCT03211793Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With
Phase 3 · 1 location(s) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Banglade · NCT06936215Investigation of Respiratory Muscle Sarcopenia in Patients With Systemic Sclerosis
Phase N/A · 1 location(s) · Selcuk University · NCT06598982
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.